Orthoptek Magnocellular Stimulator - A Revolutionary Innovative Device In The Management Of Amblyopia

The aim of this study was to evaluate the efficacy of Orthoptek (Magnocellular Stimulator OMS; Carditek Pvt. Ltd., Bangalore) as a treatment modality for amblyopia - Anisometropic , Isomyopic and Isohypermetropic and strabismus. And to assess it's effect on the peripheral Magnocellular Cells of the retina.

Improvement in best corrected visual acuity , contrast sensitivity , stereopsis were to be measured. 

Fifty-five patients with amblyopia of any type, reduced vision in one or both eyes with no binocular vision and or poor stereopsis were included in the study. All patients underwent a minimum of 10 sessions of therapy with each session lasting for a cumulative period of 60 min. At the end of the 10th session, patients were evaluated for improvement in visual acuity, stereopsis, Binocular single vision and amount of strabismus, if any.

The mean logMAR corrected distance visual acuity improved from 0.31 ± 0.34 and 0.32 ± 0.44 to 0.08 ± 0.12 and 0.07 ± 0.12 posttreatment in the right eye and left eye, respectively. Following therapy, 50 (91%) patients showed improvement in stereopsis, orthophoria was noticed in 43 (78%), and binocular single vision was noted in 48 (87%). All patients were followed up for 1 year with maintenance therapy and none showed any regression.

We believe that top–down impulses and the role of the attention area in the parietal cortex have not been studied well enough in the treatment of amblyopia. Our device addresses these issues and corrects the visual deficits in amblyopia. However, the study needs to be multicentric and with larger sample size to be more conclusive , however the present results are very much encouraging and can revolutionize management of Amblyopia.